- Details
- In this conversation, Scott Tagawa and Oliver Sartor join Charles Ryan in a discussion on the PSMAddition clinical trial that integrates lutetium-177 with standard-of-care therapy in metastatic castration-sensitive prostate cancer (mCSPC). The trial aims to determine the efficacy and safety of lutetium-177 administered earlier in the disease course. They believe that using lutetium-177 upfront wil...
|
- Details
- Oliver Sartor, MD, the CO-PI on the VISION Trial joins Alicia Morgans, MD, MPH in a conversation on the practice-changing VISION Trial results presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. 177Lu-PSMA-617 is a targeted radioligand therapy that delivers ß-particle radiation to PSMA-expressing cells and the surrounding microenvironment. The VISION study was an int...
|
- Details
- In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen highlight a systematic review and meta-analysis examining the effectiveness and toxicities of lutetium-177-labeled prostate-specific membrane antigen-targeted radioligand therapy in metastatic castration-resistant prostate cancer, an article published in European Urology. Drs. Wallis and Klaassen detail the analysis, objective,...
|
- Details
- The treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) has mostly involved androgen receptor-targeted therapies (ARTTs) and cytotoxic chemotherapy for over a decade. Lutetium-177 [177Lu]Lu-PSMA-617 is a radiolabelled small molecule that delivers β radiation to cells expressing prostate-specific membrane antigen (PSMA), with activity and safety in patients with metas...
|
- Details
- Phil Koo, MD is joined by Wolfgang Weber, MD sharing his thoughts on the current state of PSMA based therapies. Dr. Weber discusses which patients respond well to this treatment, as well as the research being done to better understand why some patients do not respond well to this treatment. Dr. Weber concludes with a glimpse of things to come for PSMA based therapies. Biographies: Wolfgang Weber,...
|
- Details
- Ian Davis, MBBS, PhD, FRACP, and Michael Hofman, MBBS, FRACP, discuss the TheraP trial with Alicia Morgans, MD, MPH, which was presented at the ASCO 2020 virtual meeting. This study showed that in men with docetaxel-treated metastatic castration-resistant prostate cancer (mCRPC), LuPSMA was more active than cabazitaxel. Drs. Hofman and Davis provide insights into how Lutetium-PSMA works mechanisti...
|
- Details
- Michael Hofman, from the Peter MacCallum Cancer Centre in Melbourne, Australia joins Charles Ryan to go "beyond the VISION Trial" discussing ongoing clinical trials with lutetium, for example, TheraP: a randomized phase 2 trial of 177Lu‐PSMA‐617 theranostic treatment vs cabazitaxel in progressive metastatic castration‐resistant prostate cancer (Clinical Trial Protocol ANZUP 1603) where results are...
|
- Details
- Scott Tagawa joins Alicia Morgans in discussing his recent research focus on radiopharmaceuticals for the treatment of prostate cancer. Dr. Tagawa highlights his studies evaluating both beta-emitting particles and alpha targeted particle therapies. Biographies: Scott T. Tagawa, MD, Associate Professor of Clinical Medicine, Clinical Urology, Medical Director, Genitourinary Oncology Research Program...
|
- Details
- Carmel Pezaro and Michael Hofman discuss the evolving role of lutetium-PSMA in the highly personalized treatment strategy for metastatic castrate-resistant prostate cancer in the era of personalized medicine. Michael Hofman discusses the research on 177Lu-DOTA-PSMA-617 (177Lu-PSMA-617), a PSMA-targeted small molecule with favorable properties and is the most extensively investigated PSMA radioliga...
|
- Details
- Where in this treatment regimen would you place lutetium-177-PSMA radioligand therapy? This was the question Harshad Kulkarni, MD posed to the audience at the start of his presentation. The aim of the study which he was presenting during this Society of Nuclear Medicine and Molecular Imaging presentation was to determine the influence of timing of lutetium PSMA radioligand therapy in metastatic pr...
|
